These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 18324952

  • 1. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.
    Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G, Delconte A.
    Int J Clin Pract; 2008 Apr; 62(4):606-13. PubMed ID: 18324952
    [Abstract] [Full Text] [Related]

  • 2. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
    Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P.
    Int J Clin Pract; 2008 Nov; 62(11):1664-74. PubMed ID: 18811599
    [Abstract] [Full Text] [Related]

  • 3. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A.
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [Abstract] [Full Text] [Related]

  • 4. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
    Hill S, Elhilali M, Millard RJ, Dwyer PL, Lheritier K, Kawakami FT, Steel M.
    Curr Med Res Opin; 2007 Nov; 23(11):2697-704. PubMed ID: 17892634
    [Abstract] [Full Text] [Related]

  • 5. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK, Fox KM, Cerulli A, Ariely R, Kahler KH, Coyne KS.
    Neurourol Urodyn; 2009 Nov; 28(5):416-22. PubMed ID: 19030182
    [Abstract] [Full Text] [Related]

  • 6. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [Abstract] [Full Text] [Related]

  • 7. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F, Stewart L, Dwyer P.
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [Abstract] [Full Text] [Related]

  • 8. Time-to-effect with darifenacin in overactive bladder: a pooled analysis.
    Khullar V, Foote J, Seifu Y, Egermark M.
    Int Urogynecol J; 2011 Dec; 22(12):1573-80. PubMed ID: 22006023
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [Abstract] [Full Text] [Related]

  • 10. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 11. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M.
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Robinson D.
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [Abstract] [Full Text] [Related]

  • 13. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, Abrams P.
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [Abstract] [Full Text] [Related]

  • 14. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S, Khullar V, Wyndaele JJ, Lheritier K, Darifenacin Study Group.
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [Abstract] [Full Text] [Related]

  • 15. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P, Kelleher C, Young J, Haab F, Lheritier K, Ariely R, Ebinger U.
    Neurourol Urodyn; 2008 May; 27(6):540-7. PubMed ID: 18663723
    [Abstract] [Full Text] [Related]

  • 16. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J, Glavind K, Kralidis G, Wyndaele JJ.
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [Abstract] [Full Text] [Related]

  • 17. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
    Cardozo L, Dixon A.
    J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
    [Abstract] [Full Text] [Related]

  • 18. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
    Mattiasson A, Masala A, Morton R, Bolodeoku J, SOLAR Study Group.
    BJU Int; 2010 Apr; 105(8):1126-35. PubMed ID: 19818077
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
    Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F.
    Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.